$MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Jon Congleton
CEO
51
Employees
$24.07
Current Price
$1.85B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $10,696.05 | 417 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 6 | $611,939.08 | 22,994 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 6 | $611,939.08 | 22,994 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 13 | $1,258,839.07 | 45,986 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 24 | $12,309,037.55 | 363,742 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 6,348 | $32.32 | $205,143.24 | View Details |
| Jan 2, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 70,037 | $35.87 | $2,511,919.03 | View Details |
| Jan 5, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 139,245 | $34.83 | $4,849,555.24 | View Details |
| Jan 5, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 53,470 | $35.53 | $1,899,553.83 | View Details |
49 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ24 of 24 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.52
Actual-$0.40
Beat
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.57
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.57
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$SRRK โ Scholar Rock Holding Corpvia AKKARAJU SRINIVAS$KLRS โ Kalaris Therapeutics, Inc.via AKKARAJU SRINIVAS$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.$ALMS โ Alumis Inc. Common Stockvia AKKARAJU SRINIVAS$TYRA โ Tyra Biosciences, Inc.via RA CAPITAL MANAGEMENT, L.P.